TrialActa pharmaceutica Sinica. B2023

Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial.

Binghe Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.